YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$11.98 USD
-0.33 (-2.68%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $12.00 +0.02 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
YMAB 11.98 -0.33(-2.68%)
Will YMAB be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for YMAB
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
New Strong Buy Stocks for April 19th
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for April 17th
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
Other News for YMAB
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
Y-mAbs Therapeutics announces preclinical GD2-SADA to be presented at SNMMI
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
Y-mAbs Therapeutics appoints LaFrance as Chief Development Officer
Y-mAbs Therapeutics announces publication of preclinical GD2-SADA data at ASCO